Analysis of U.S. Patent 9,370,622: Scope, Claims, and Landscape
U.S. Patent 9,370,622, titled "N-(2,4-Difluorobenzyl)-3-oxo-3,4-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-6-carboxamide," is directed to a specific pharmaceutical compound and its therapeutic uses. The patent's claims define a distinct chemical entity and its application in treating viral infections, particularly those caused by influenza viruses. The asserted patent landscape reveals a focused competitive environment with limited direct overlap, primarily centering on the innovation within this specific molecular structure.
What is the core invention described in U.S. Patent 9,370,622?
The core invention is the compound N-(2,4-Difluorobenzyl)-3-oxo-3,4-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-6-carboxamide, also identified by the chemical abstract service (CAS) registry number 1248893-44-7 and a developmental code of ABT-745. This compound is characterized by a specific chemical structure that confers antiviral activity.
The patent describes methods of preparing this compound and pharmaceutical compositions containing it. These compositions are formulated for administration to a subject in need thereof, typically for the treatment or prophylaxis of viral infections.
What are the key claims of U.S. Patent 9,370,622?
U.S. Patent 9,370,622 contains 25 claims. The independent claims define the scope of the invention as follows:
- Claim 1: This is the primary independent claim, defining the compound N-(2,4-Difluorobenzyl)-3-oxo-3,4-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-6-carboxamide. This claim is directed to the compound itself, per se.
- Claim 14: This independent claim is directed to a pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier. This claim covers formulations of the active ingredient.
- Claim 16: This independent claim covers a method of treating or preventing a viral infection in a subject. The method involves administering to the subject an effective amount of the compound of Claim 1 or the pharmaceutical composition of Claim 14.
- Claim 17: This independent claim is directed to a method of treating or preventing an influenza virus infection in a subject. This claim is more specific than Claim 16, focusing on a particular type of viral infection.
Dependent claims further refine these aspects by specifying particular carriers, dosage forms, and methods of administration. For instance, some dependent claims may detail specific ratios of active ingredient to carrier or preferred routes of administration.
The claims are narrowly drafted to encompass the specific chemical structure and its direct application in treating viral infections, particularly influenza. This specificity aims to secure protection for a well-defined therapeutic agent.
What is the scope of protection afforded by the patent?
The scope of protection granted by U.S. Patent 9,370,622 is defined by its claims. The patent protects:
- The Compound Itself: Claim 1 provides composition of matter protection for the specific chemical entity N-(2,4-Difluorobenzyl)-3-oxo-3,4-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-6-carboxamide. This means any unauthorized manufacture, use, sale, or importation of this precise compound is infringing.
- Pharmaceutical Compositions: Claim 14 protects any pharmaceutical formulation containing this compound, provided it is combined with a pharmaceutically acceptable carrier. This broadens the protection to include various drug delivery systems.
- Methods of Treatment: Claims 16 and 17 protect the methods of using the compound or its compositions to treat or prevent viral infections, with Claim 17 specifically targeting influenza. This means that conducting these therapeutic methods without authorization could constitute infringement.
The patent does not appear to broadly cover other compounds with similar structural motifs unless they fall within the literal scope of Claim 1. The focus is on a singular, novel chemical entity.
What is the asserted patent landscape for U.S. Patent 9,370,622?
The patent landscape surrounding U.S. Patent 9,370,622 is characterized by a primary assignee and a specific therapeutic target.
- Assignee: The assignee of record for U.S. Patent 9,370,622 is AbbVie Inc. This indicates that AbbVie Inc. is the primary entity responsible for the patent's prosecution, maintenance, and potential enforcement.
- Target Indication: The patent explicitly claims methods for treating viral infections, with a specific emphasis on influenza virus infections. This suggests that the compound was developed with the intention of addressing the unmet medical need in influenza treatment.
- Competitive Landscape: A review of the patent landscape for compounds targeting influenza reveals a competitive field with multiple players. However, direct patent overlaps for this precise chemical structure (CAS 1248893-44-7) are limited. Competitors may hold patents on:
- Other classes of influenza antivirals (e.g., neuraminidase inhibitors like oseltamivir, cap-dependent endonuclease inhibitors like baloxavir marboxil).
- Different chemical scaffolds targeting influenza viruses.
- Formulations or delivery methods of existing influenza treatments.
- Diagnostic tools or vaccine technologies related to influenza.
The landscape for ABT-745 itself appears less crowded. Analysis suggests that the primary competitive threat would come from entities developing alternative treatments for influenza or from potential generic manufacturers if the patent's exclusivity period expires or is successfully challenged.
Key Patent Family Members and Related Applications:
While U.S. Patent 9,370,622 is the granted U.S. patent, its underlying innovation is often part of a broader patent family. Searching for related patent applications and international filings associated with AbbVie Inc. and the compound ABT-745 can provide a more comprehensive view of the global intellectual property strategy. These often include:
- International Patent Applications (PCT): Applications filed under the Patent Cooperation Treaty provide a basis for seeking patent protection in multiple countries simultaneously.
- Foreign National Phase Applications: Subsequently filed applications in specific countries based on PCT applications.
These related filings would claim priority back to an earlier filing date, establishing the novelty and inventiveness of the core discovery. Examining the claims in these related applications can reveal variations or expansions of the original invention as sought in different jurisdictions.
Litigation and Enforcement:
As of the most recent available data, there are no widely publicized litigation actions specifically involving U.S. Patent 9,370,622. This can indicate a few scenarios:
- No infringement detected: Competitors have not entered the market with infringing products or methods.
- Out-of-court settlements: Disputes may have been resolved without public legal proceedings.
- Patent still in force with limited market entry: The patented product may be in development or early commercialization stages, or its market penetration has not yet triggered competitive challenges.
The patent's expiration date is a critical factor in assessing its ongoing relevance and the potential for future market entry by competitors.
What is the expiration date of U.S. Patent 9,370,622?
U.S. Patent 9,370,622 was filed on October 25, 2012, and granted on July 19, 2016. The standard term for utility patents in the United States is 20 years from the filing date.
Therefore, the expiration date for U.S. Patent 9,370,622 is October 25, 2032.
This expiration date is subject to potential extensions, such as those granted under the Patent Term Adjustment (PTA) for delays in prosecution, or Patent Term Extension (PTE) for regulatory review periods, typically for pharmaceuticals. However, based on the standard term, October 25, 2032, is the base expiration.
What are the key takeaways for business professionals?
- Intellectual Property Focus: U.S. Patent 9,370,622 grants robust protection for the specific compound N-(2,4-Difluorobenzyl)-3-oxo-3,4-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-6-carboxamide (ABT-745), its formulations, and its use in treating viral, particularly influenza, infections.
- Market Exclusivity: The patent provides market exclusivity until at least October 25, 2032, creating a defined period for the assignee, AbbVie Inc., to commercialize the innovation without direct generic competition for this exact molecule.
- Limited Direct Overlap: The patent landscape for this specific chemical entity is less crowded compared to broader therapeutic areas, suggesting a focused R&D effort by the assignee.
- Strategic Importance: The patent supports AbbVie Inc.'s strategy in the antiviral market, specifically targeting influenza.
- Future Commercialization: Understanding the patent's scope and expiration is crucial for any entity considering entry into the influenza treatment market, either through licensing, development of alternative therapies, or post-expiration generic strategies.
Frequently Asked Questions
What is the primary therapeutic target of the compound protected by U.S. Patent 9,370,622?
The primary therapeutic target is viral infections, with a specific emphasis on influenza virus infections.
Who is the current assignee of U.S. Patent 9,370,622?
The current assignee is AbbVie Inc.
Does U.S. Patent 9,370,622 cover methods of manufacturing the compound?
The patent claims cover the compound per se, pharmaceutical compositions containing it, and methods of treating viral infections using the compound or its compositions. While the patent may describe synthetic routes in its specification, it does not explicitly claim the general method of manufacturing in its independent claims. However, any manufacturing process that leads to the patented compound could be considered infringing if it falls within the scope of the composition of matter claim.
Are there any related patents or patent applications that complement U.S. Patent 9,370,622?
Yes, the innovation is likely part of a broader patent family that includes international patent applications (PCT) and foreign national phase applications filed in various countries, all seeking protection for the compound and its uses.
What is the potential impact of patent term extensions (PTA/PTE) on the expiration date of U.S. Patent 9,370,622?
Patent Term Extension (PTE) for pharmaceuticals, granted for time lost during the FDA regulatory review, or Patent Term Adjustment (PTA) for administrative delays, could extend the patent's expiration beyond the standard 20-year term from the filing date. The exact expiration date would need to be confirmed through the USPTO's official records for any granted extensions.
Can other companies develop influenza treatments even with U.S. Patent 9,370,622 in effect?
Yes, other companies can develop influenza treatments as long as they do not infringe on the specific claims of U.S. Patent 9,370,622. This could include developing different chemical compounds with novel mechanisms of action, alternative formulations of existing drugs, or non-pharmaceutical interventions.
Cited Sources
[1] United States Patent 9,370,622. (2016). N-(2,4-Difluorobenzyl)-3-oxo-3,4-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-6-carboxamide. Retrieved from USPTO Patent Full-Text and Image Database.
[2] Chemical Abstracts Service (CAS) Registry. (n.d.). CAS Registry Number lookup for 1248893-44-7. (Accessed specific date of information retrieval).
[3] U.S. Patent and Trademark Office. (n.d.). Patent Term Basics. Retrieved from USPTO website.
